Greenleaf Trust lowered its position in Danaher Corporation (NYSE:DHR - Free Report) by 6.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 93,343 shares of the conglomerate's stock after selling 6,166 shares during the quarter. Greenleaf Trust's holdings in Danaher were worth $19,135,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Danaher by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 59,750,122 shares of the conglomerate's stock valued at $13,715,641,000 after purchasing an additional 315,912 shares during the last quarter. Geode Capital Management LLC boosted its stake in Danaher by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate's stock worth $3,056,996,000 after buying an additional 315,446 shares in the last quarter. Norges Bank bought a new position in Danaher during the fourth quarter valued at approximately $2,130,740,000. Bank of New York Mellon Corp raised its stake in shares of Danaher by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock worth $1,800,614,000 after acquiring an additional 194,466 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Danaher by 14.3% in the 4th quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate's stock worth $1,821,477,000 after acquiring an additional 992,594 shares during the last quarter. Institutional investors own 79.05% of the company's stock.
Danaher Stock Up 0.1%
Shares of NYSE DHR traded up $0.25 during midday trading on Wednesday, hitting $200.93. The stock had a trading volume of 2,050,741 shares, compared to its average volume of 3,496,423. The business's 50 day moving average is $195.74 and its 200-day moving average is $206.85. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. The company has a market cap of $143.80 billion, a P/E ratio of 39.02, a PEG ratio of 2.80 and a beta of 0.77.
Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The firm had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. As a group, analysts predict that Danaher Corporation will post 7.63 EPS for the current year.
Danaher Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.64%. Danaher's payout ratio is currently 24.85%.
Insiders Place Their Bets
In other news, Chairman Steven M. Rales sold 1,250,000 shares of the company's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the sale, the chairman directly owned 3,105,808 shares in the company, valued at $611,036,665.92. This represents a 28.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the transaction, the executive vice president owned 15,179 shares in the company, valued at $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on DHR. Robert W. Baird decreased their target price on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 23rd. Wolfe Research lowered their target price on Danaher from $275.00 to $220.00 and set an "outperform" rating for the company in a research note on Monday, April 7th. Jefferies Financial Group dropped their target price on Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a report on Tuesday, April 22nd. Evercore ISI lowered their price objective on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research report on Tuesday. Finally, Royal Bank Of Canada reissued an "outperform" rating and set a $250.00 price objective on shares of Danaher in a research note on Wednesday, April 23rd. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and a consensus price target of $248.00.
Get Our Latest Research Report on DHR
About Danaher
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Stories
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
